Pyroptosis in lung cancer: The emerging role of non-coding RNAs

IF 2.9 4区医学 Q2 PATHOLOGY Pathology, research and practice Pub Date : 2024-09-28 DOI:10.1016/j.prp.2024.155619

Lakshmi Thangavelu , Ahsas Goyal , Muhammad Afzal , Ehssan Moglad , Sushama Rawat , Imran Kazmi , Sami I. Alzarea , Waleed Hassan Almalki , Richa Rani , Pusuluri Madhubabu , Pranchal Rajput , Pooja Bansal

{"title":"Pyroptosis in lung cancer: The emerging role of non-coding RNAs","authors":"Lakshmi Thangavelu , Ahsas Goyal , Muhammad Afzal , Ehssan Moglad , Sushama Rawat , Imran Kazmi , Sami I. Alzarea , Waleed Hassan Almalki , Richa Rani , Pusuluri Madhubabu , Pranchal Rajput , Pooja Bansal","doi":"10.1016/j.prp.2024.155619","DOIUrl":null,"url":null,"abstract":"<div><div>Lung cancer remains an intractable malignancy worldwide, prompting novel therapeutic modalities. Pyroptosis, a lethal form of programmed cell death featured by inflammation, has been involved in cancer progression and treatment response. Simultaneously, non-coding RNA has been shown to have important roles in coordinating pattern formation and oncogenic pathways, including long non-coding RNA (lncRNAs), microRNA (miRNAs), circular RNA (circRNAs), and small interfering RNA (siRNAs). Recent studies have revealed that ncRNAs can promote or inhibit pyroptosis by interacting with key molecular players such as NLRP3, GSDMD, and various transcription factors. This dual role of ncRNAs offers a unique therapeutic potential to manipulate pyroptosis pathways, providing opportunities for innovative cancer treatments. In this review, we integrate current research findings to propose novel strategies for leveraging ncRNA-mediated pyroptosis as a therapeutic intervention in lung cancer. We explore the potential of ncRNAs as biomarkers for predicting patient response to treatment and as targets for overcoming resistance to conventional therapies.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"263 ","pages":"Article 155619"},"PeriodicalIF":2.9000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033824005302","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer remains an intractable malignancy worldwide, prompting novel therapeutic modalities. Pyroptosis, a lethal form of programmed cell death featured by inflammation, has been involved in cancer progression and treatment response. Simultaneously, non-coding RNA has been shown to have important roles in coordinating pattern formation and oncogenic pathways, including long non-coding RNA (lncRNAs), microRNA (miRNAs), circular RNA (circRNAs), and small interfering RNA (siRNAs). Recent studies have revealed that ncRNAs can promote or inhibit pyroptosis by interacting with key molecular players such as NLRP3, GSDMD, and various transcription factors. This dual role of ncRNAs offers a unique therapeutic potential to manipulate pyroptosis pathways, providing opportunities for innovative cancer treatments. In this review, we integrate current research findings to propose novel strategies for leveraging ncRNA-mediated pyroptosis as a therapeutic intervention in lung cancer. We explore the potential of ncRNAs as biomarkers for predicting patient response to treatment and as targets for overcoming resistance to conventional therapies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肺癌中的脓毒症：非编码 RNA 的新作用

肺癌仍然是全球范围内难以治愈的恶性肿瘤，因此需要新的治疗方法。炎症导致的一种致命的细胞程序性死亡形式--嗜热细胞增多症（Pyroptosis）与癌症进展和治疗反应有关。同时，非编码 RNA（包括长非编码 RNA（lncRNA）、microRNA（miRNA）、环状 RNA（circRNA）和小干扰 RNA（siRNA））已被证明在协调模式形成和致癌途径中具有重要作用。最近的研究发现，ncRNA 可通过与 NLRP3、GSDMD 和各种转录因子等关键分子角色相互作用，促进或抑制脓毒症。ncRNA 的这种双重作用为操纵化脓途径提供了独特的治疗潜力，为创新癌症治疗提供了机会。在这篇综述中，我们整合了当前的研究成果，提出了利用 ncRNA 介导的热蛋白沉积作为肺癌治疗干预的新策略。我们探讨了 ncRNA 作为生物标记物预测患者对治疗反应的潜力，以及作为靶点克服传统疗法耐药性的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.